Alyeska Investment Group L.P. lowered its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 37.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 248,846 shares of the medical technology company's stock after selling 150,000 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.18% of Alphatec worth $2,284,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Barclays PLC grew its position in Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after buying an additional 133,653 shares during the period. Courier Capital LLC boosted its stake in shares of Alphatec by 76.9% during the 4th quarter. Courier Capital LLC now owns 69,000 shares of the medical technology company's stock worth $633,000 after acquiring an additional 30,000 shares during the last quarter. Ballentine Partners LLC bought a new stake in shares of Alphatec during the 4th quarter valued at $120,000. Nisa Investment Advisors LLC increased its stake in shares of Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after purchasing an additional 4,234 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC bought a new position in Alphatec in the 4th quarter worth $152,000. Hedge funds and other institutional investors own 66.35% of the company's stock.
Wall Street Analyst Weigh In
ATEC has been the subject of a number of analyst reports. Barclays upped their price target on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Piper Sandler restated an "overweight" rating and set a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Alphatec currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.89.
Check Out Our Latest Report on ATEC
Insider Buying and Selling at Alphatec
In other Alphatec news, CEO Patrick Miles sold 32,393 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $10.89, for a total transaction of $352,759.77. Following the completion of the sale, the chief executive officer now directly owns 5,940,391 shares of the company's stock, valued at approximately $64,690,857.99. This represents a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Sponsel sold 12,946 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $10.73, for a total transaction of $138,910.58. Following the transaction, the executive vice president now owns 722,128 shares of the company's stock, valued at approximately $7,748,433.44. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 126,945 shares of company stock valued at $1,416,352 in the last quarter. 20.90% of the stock is owned by insiders.
Alphatec Trading Up 2.8%
Shares of Alphatec stock traded up $0.34 on Monday, reaching $12.55. The company had a trading volume of 218,526 shares, compared to its average volume of 2,110,072. The firm's 50-day moving average price is $10.50 and its two-hundred day moving average price is $10.16. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $12.82. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -9.80 and a beta of 1.06. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.
Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The firm had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The company's revenue was up 22.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.34) EPS. As a group, research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.
About Alphatec
(
Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
See Also

Before you consider Alphatec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.
While Alphatec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.